HIV Dementia
- PMID: 14759346
- DOI: 10.1007/s11940-004-0023-6
HIV Dementia
Abstract
Dementia and milder forms of cognitive impairment are important manifestations, with important socioeconomic consequences, of HIV infection. Early detection and aggressive treatment are essential to achieve stabilization and prevent progression. In some affected individuals, reversal of symptoms may follow initiation of effective therapy. Antiretroviral treatment needs to be individualized, taking into consideration the relative central nervous system penetration of the drugs, presence of drug resistant viral strains, possible drug interactions, and drug side effect profiles. Combination antiretroviral therapy is preferred. Zidovudine, stavudine, abacavir, navirapine and indinavir have relatively good penetration into the central nervous system. The aim of therapy should be for control of viral load in the periphery and the cerebrospinal fluid. Furthermore, although not established therapy, the use of neuroprotective agents and anti-inflammatory regimens may be considered. A comprehensive multidisciplinary approach to management with regular follow-up is essential for treatment.
Similar articles
-
Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine.Lancet. 1998 May 23;351(9115):1547-51. doi: 10.1016/S0140-6736(98)07333-4. Lancet. 1998. PMID: 10326538 Clinical Trial.
-
Changes in cognition during antiretroviral therapy: comparison of 2 different ranking systems to measure antiretroviral drug efficacy on HIV-associated neurocognitive disorders.J Acquir Immune Defic Syndr. 2009 Sep 1;52(1):56-63. doi: 10.1097/qai.0b013e3181af83d6. J Acquir Immune Defic Syndr. 2009. PMID: 19731418
-
A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.AIDS. 1999 Dec 3;13(17):2377-88. doi: 10.1097/00002030-199912030-00009. AIDS. 1999. PMID: 10597779 Clinical Trial.
-
Didanosine: an updated review of its use in HIV infection.Drugs. 1999 Dec;58(6):1099-135. doi: 10.2165/00003495-199958060-00009. Drugs. 1999. PMID: 10651392 Review.
-
Abacavir: a review of its clinical potential in patients with HIV infection.Drugs. 2000 Aug;60(2):447-79. doi: 10.2165/00003495-200060020-00015. Drugs. 2000. PMID: 10983741 Review.
Cited by
-
Purinergic signaling in infectious diseases of the central nervous system.Brain Behav Immun. 2020 Oct;89:480-490. doi: 10.1016/j.bbi.2020.07.026. Epub 2020 Jul 24. Brain Behav Immun. 2020. PMID: 32717399 Free PMC article. Review.
-
HIV-Proteins-Associated CNS Neurotoxicity, Their Mediators, and Alternative Treatments.Cell Mol Neurobiol. 2022 Nov;42(8):2553-2569. doi: 10.1007/s10571-021-01151-x. Epub 2021 Sep 25. Cell Mol Neurobiol. 2022. PMID: 34562223 Free PMC article. Review.
-
Human Coronaviruses and Other Respiratory Viruses: Underestimated Opportunistic Pathogens of the Central Nervous System?Viruses. 2019 Dec 20;12(1):14. doi: 10.3390/v12010014. Viruses. 2019. PMID: 31861926 Free PMC article. Review.
-
Neuroinvasive and neurotropic human respiratory coronaviruses: potential neurovirulent agents in humans.Adv Exp Med Biol. 2014;807:75-96. doi: 10.1007/978-81-322-1777-0_6. Adv Exp Med Biol. 2014. PMID: 24619619 Free PMC article. Review.
-
When human immunodeficiency virus meets chemokines and microglia: neuroprotection or neurodegeneration?J Neuroimmune Pharmacol. 2013 Mar;8(1):118-31. doi: 10.1007/s11481-012-9353-4. Epub 2012 Apr 15. J Neuroimmune Pharmacol. 2013. PMID: 22527632 Free PMC article. Review.
References
LinkOut - more resources
Full Text Sources
Other Literature Sources